Comparison of Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and Magnetic Resonance Spectroscopy (MRS) as Bioenergetic Imaging Modalities in Healthy Human Brain and Major Depressive Disorder
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Paul Carlson
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- high energy phosphate metabolites (Phosphocreatine (PCr)) as measured by magnetic resonance spectroscopy
研究概览
简要总结
Several lines of evidence support the existence of an underlying abnormality in brain energy metabolism may play a key role in the biology of mood disorders. The current study utilizes two distinct but complementary imaging techniques, fluorodeoxyglucose (FDG) positron emission tomography (PET) and multinuclear magnetic resonance spectroscopy (MRS), to better understand the nature of these metabolic abnormalities in major depressive disorder (MDD). The investigators hypothesize that individuals with depression will have increased metabolic activity as measured by PET in certain brain regions involved in mood regulation, but that this metabolic activity will be inefficient based on MRS findings. For this study, the investigators will study 10 medication-free, currently depressed participants with recurrent MDD, 10 depressed participants with recurrent MDD currently taking antidepressant medication, and up to 20 healthy control participants matched to depressed participants for age and gender. Depressed and healthy participants will each undergo one PET scan and one MRS scanning session.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Meet DSM-IV criteria for Major Depressive Disorder (MDD), Recurrent
- •Montgomery-Asberg Depression Rating Scale (MADRS) score > 18
排除标准
- •Any coexisting psychiatric illness other than generalized anxiety disorder, panic disorder, or social/specific phobias
- •Any history of substance dependence
- •Substance abuse within the past 6 months
- •Significant risk of suicide, as defined by score >4 on item 10 of the MADRS or in the clinical judgment of the study physician
- •Any significant medical or neurological condition which is likely to impact the central nervous system and/or affect the results of MRS or PET imaging
- •For the subset of unmedicated MDD patients, any psychotropic medications within 4 weeks prior to scanning. For the subgroup of medicated patients, they may be taking a stable dose (i.e., same dose for at least 4 weeks at the time of scanning) of standard antidepressant medications, but may not be taking any other psychotropic medication.
- •Inability to give informed consent
- •Contraindication to MRI (e.g., pacemaker, ferromagnetic implants in the body)
结局指标
主要结局
high energy phosphate metabolites (Phosphocreatine (PCr)) as measured by magnetic resonance spectroscopy
时间窗: cross-sectional
relative concentration of Pcr
次要结局
- regional cerebral glucose metabolism, as measured by Positron Emission Tomography (PET)(cross-sectional)
- N-Acetyl-Aspartate (NAA) metabolite intensity, as measured by proton Magnetic Resonance Spectroscopy (MRS)(cross-sectional)
- severity of depressive symptoms, as scored on the Montgomery-Asberg Depression Rating Scale (MADRS)(cross-sectional)
研究者
Paul Carlson
Assistant Professor
University of Utah